Group 1 - The core achievement of Shandong Borui Laser Technology Co., Ltd. is securing third place in the 14th China Innovation and Entrepreneurship Competition in Shandong, highlighting its successful high-end pulsed laser industrialization project [1] - The company faced significant funding challenges due to the high costs and long cycles associated with high-end laser research and development, which were exacerbated by an increase in order volume [3][6] - Traditional loan requirements posed difficulties for the company, as they primarily rely on technology and equipment rather than real estate for collateral [3] Group 2 - The introduction of the "Jidang-Entrepreneur Loan" policy provided a crucial financial lifeline for the company, allowing them to access loans without collateral and with government subsidies [6][11] - The loan application process has been streamlined through digital transformation, reducing approval times from an average of 15 days to as little as 3 days [8][11] - The financial support from the "Jidang-Entrepreneur Loan" has enabled the company to acquire new testing equipment and fulfill key orders, contributing to its recognition as a provincial-level gazelle enterprise [6][11] Group 3 - The "Jidang-Entrepreneur Loan" program has significantly reduced the cost of financing for the company, with government subsidies lowering the effective interest rate to 1.75% [11][13] - From January to July of this year, the program has provided 1.006 billion yuan in new entrepreneurial guarantee loans, ranking second in the province [13] - The program has supported approximately 45,000 stable jobs through its financing efforts, demonstrating its impact on employment [13]

Core Viewpoint - The beauty and cosmetic surgery market in China is rapidly expanding, with an estimated market size of nearly 300 billion yuan in 2024 [1]. Regulatory Developments - The National Healthcare Security Administration (NHSA) has issued a guideline to standardize pricing for commonly used cosmetic surgery services, addressing the prevalent issue of price discrepancies in the booming market [2][4]. - The guideline does not alter the market-based pricing management but aims to unify project names and standardize pricing behaviors among medical institutions [4]. Pricing Structure - Medical institutions can set their own prices for cosmetic surgery services, leading to significant price variations. The new guideline categorizes established procedures under unified names and standardizes abstract pricing projects [4][6]. - The guideline allows for the inclusion of popular treatments under specific categories, such as "ultrasound treatment" and "radiofrequency treatment," to enhance clarity in pricing [6]. Customization and Innovation - The guideline reflects the diverse and personalized needs of patients, allowing for detailed categorization of common procedures, such as lip enhancement [8]. - Medical institutions are permitted to establish additional charges for new technologies and equipment, subject to local healthcare department approval [8]. New Pricing Projects - The guideline introduces new pricing projects for "reduction of scarring through cosmetic suturing" and "surgical incision beautification," encouraging medical professionals to minimize scarring from the outset [9][11]. - A new charge for "revision surgery" has been established, recognizing the increased complexity and difficulty of follow-up procedures compared to initial surgeries [12][14].

南京波长光电科技股份有限公司 首次公开发行股票并在创业板上市发行公告 保荐人（主承销商）：华泰联合证券有限责任公司 特别提示 根据《国民经济行业分类》（GB/T 4754-2017），南京波长光电科技股份有限 公司（以下简称"波长光电"、"发行人"或"公司"）所属行业为"仪器仪表制造业 （C40）"，细分行业为"光学仪器制造（C4040）"。截至 2023 年 8 月 8 日(T-4 日)， 中证指数有限公司发布的"C40 仪器仪表制造业"最近一个月平均静态市盈率为 39.05 倍。本次发行价格 29.38 元/股对应的发行人 2022 年扣除非经常性损益前 后孰低的摊薄后市盈率为 60.67 倍，高于可比公司 2022 年扣非后平均静态市盈 率，超出幅度为 18.13%；高于中证指数有限公司发布的行业最近一个月平均静 态市盈率，超出幅度为 55.37%，可能存在未来发行人股价下跌给投资者带来损 失的风险。发行人和保荐人（主承销商）提请投资者关注投资风险，审慎研判发 行定价的合理性，理性作出投资。 波长光电根据中国证券监督管理委员会（以下简称"中国证监会"）颁布的 《证券发行与承销管理办法》（证监会令[第 2 ...